On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

MannKind Corp. (MNKD) Now Poised to Exploit Pole Position in Inhalable Insulin, as well as Microparticle Formulation and Delivery Tech

We live in a business world characterized by an immediate, never-ceasing deluge of information. A veritable tsunami of opinions, perspectives, scoped analysis, and technical speculation hits us in the face every hour of the day, seven days each week, for 365 days out of the year. On any given subject, you name the position and chances are that someone, touted as an expert in some circle or circles, has argued it as if it were fact or a foregone conclusion. But history is written by the contrarians, by underdogs and innovators who understood the raw force of demand present in the markets of their time, and assembled the requisite capital, expertise, materials, and technology to execute.

While the talking heads have been busy this week panning diabetes and cancer-focused inhalable therapeutics, developer MannKind Corporation (NASDAQ: MNKD), after an EPS miss for Q4 that shrugged off the Zacks Research consensus of only a $0.05 loss, it is important to look at the bigger picture. The big picture here is about the core technologies and how they can address unmet and underserved demand in the market. It’s a long-term success story in the making and it is a good one. It’s not just under reportage of how significant French biopharma giant Sanofi’s (NYSE: SNY) marketing agreement pullout in January was in terms of overall financial performance for the company and its commercial success with its novel inhalable insulin product Afrezza, or that to many observers Sanofi was clearly dragging their feet with marketing efforts, it’s that MannKind is far more than some one-trick pony.

Nevertheless, Afrezza is a damn good trick considering the projections for diabetes incidence rates worldwide, with seven million more patients per year added to the rolls, and the fact that both the drug and delivery mechanism are categorically different than anything that has come to market hitherto. Afrezza is an ultra-rapid-acting insulin in powder form created for primary use as a pre-meal adult insulin in type one and two diabetics, engineered to be used in conjunction with existing treatments in order to help squash post-meal blood spikes. While famous for being the first company daring enough to throw its hat in the inhalable insulin ring since the spectacular failure of Pfizer (NYSE: PFE) that culminated back in 2007’s Exubera market withdrawal, MannKind is also the company that engineered the Technosphere® formulation and drug delivery platform behind the efficacy of Afreeza (based on acid-induced self-assembly of fumaryl diketopiperazine molecules), an extremely versatile breath-powered drug delivery platform that allows for inhalable variants of indications currently available only via injection.

The capacity to formulate Technosphere microparticles from a wide range of drugs with varying physicochemical characteristics does far more for MNKD than to merely enable its inhaler-based delivery technologies, like the proprietary, small form factor (and therefore discrete), yet hugely efficient Dreamboat® inhaler (http://dtn.fm/6aXEI). This technology opens up the potential for MNKD to become a formulation and delivery mechanism powerhouse for numerous existing drugs. Technosphere microparticles present vastly improved bioavailability characteristics and avoid the common problem with many drugs, which experience dosage degradation in peripheral circulation. While simultaneously avoiding the hepatic (of or relating to the liver) first-pass effect typical in orally administered drugs (and most readily observable in drugs such as morphine), where a significant portion of the administered drug is lost before it ever reaches the target, due to intestinal and hepatic degradation of the dose. The highly efficient and versatile Technosphere platform is able to produce formulations which closely mimic the pharmacokinetics of intraarterial administration (injection directly into an artery), and also offers a bold new pathway for vehicle-controlled (much like a placebo, but with better data fidelity/feedback) clinical studies to be conducted using “blanks,” or Technosphere microparticles onto which no drug in the 500 to 140,000 Da range of molecular weight (note the breadth of molecular weight range) has been adsorbed.

Some intelligent analysts in the investment community have noted similar issues for MNKD’s flagship product that cropped up during the poor reception of Pfizer’s Exubera, such as the novelty of inhalable insulin for both doctors and insurers leading to slow adoption rates, as well as bureaucratic red tape that hindered uptake by users, even when they knew about and wanted to switch to an easier to use form of insulin. A few analysts have even speculated that the entrenched logistics behind the gargantuan diabetes care devices market, which is on track to hit nearly $11 billion in North America alone by 2019 (according to a recent report published by Mordor Intelligence) and includes glucose monitoring and delivery devices such as syringes, may even be actively sandbagging the emergence of an inhalable insulin, as it represents something of an end-run on much of the space. Whether or not Sanofi helped maintain the status quo and never had any intention of really getting Afrezza into the hands of what will likely be some 380 million diabetics by 2025, or whether the EPS consensus was faulty – one thing is certain: Afrezza has failed to make the impact that its ease of use, pharmacokinetics, and the glowing comments of its lucky recipients would otherwise indicate.

Management actually sees the Sanofi split as a plus, with MNKD regaining control of its baby and being able to give it the much needed tender loving care it requires marketing-wise, in order to ignite a revolution among diabetics at the point of purchase. Let’s not forget that inhalable insulin represents a sea-change for everyone in the healthcare ecosystem either, especially the end users, who have been conditioned to think about insulin as an injectable drug over countless decades. Afrezza only launched in February of 2015 and with lukewarm marketing efforts (including huge delays, direct-to-consumer ad vaporware, and allegations about a hiring freeze on sales reps for Afrezza), as well as the drug being somewhat hamstrung initially on the insurance side of the equation, it’s no wonder MannKind can’t wait to get their hands on the reigns again. The company has even launched a significant effort to master the sales approach and pricing strategy it will need to make Afrezza the blockbuster that management and its diehard investors have longed for.

But let’s not concern ourselves too long with the mystery as to why an inhalable insulin, which a majority of users generally felt helped them more readily address the lifestyle complications associated with administering diabetic medications, (whether because it was inhalable, the inhaler was tiny, or it allowed them to dose right at the table in a restaurant, etc.) failed to go viral – and get back to the core takeaway that most investors should be focused on: the intrinsic value of the company’s IP, and its current market position.

Greek poet and mercenary Archilochus once said that the “fox knows many tricks, but the hedgehog only one: one good one,” referring to the spiny mammals’ ability to curl itself into a ball of spikes as being somewhat superior to the complex trickery and cunning of the fox. It is an apt comparison for MannKind’s market position with Afrezza, but investors should be looking closely at the company’s underlying platform technologies for drug formulation and delivery, as well as things like the Receptor Life Sciences collaboration and license agreement, designed to exploit the company’s inhaled formulation technologies. Similarly, the retention of Michael Castagna (Pharm.D) as CCO, to spearhead the Afrezza commercialization campaign and liaise directly with CEO Pfeffer, speaks volumes about how seriously the company intends to leverage its exceptional market position in inhalable insulin. Former VP of Global Lifecycle Management and Global Commercial Lead for a nine-drug portfolio at biotech giant Amgen (NASDAQ: AMGN), as well as Executive Director for Bristol-Myers Squibb’s (NYSE: BMY) immunology franchise during the launch and re-launch of its Orencia rheumatoid arthritis offerings, Castagna is by all accounts the right man to plant the Afrezza flag in spectacular fashion.

The EPS miss is logical given everything that transpired in late 2014 and during 2015, there is far more to the company than most talking heads consider and MNKD’s Technosphere dry powder delivery platform and formulation technologies could reshape the industry as we have known it, via patient-friendly, and needle-free devices for a wide variety of drugs, presented in ultra-rapid absorption form. But if you listen to the loudest voices who are screaming that the sky is falling all over again with Afrezza and that MNKD is doomed with its inhalable insulin play, you would think that the company’s flagship was all there is to this story. Naturally, many investors are quite often wed into a failed marriage of associations as a result of listening to such loud voices and end up struggling like muppets, ultimately weighed down by a dead-end momentum play portfolio.

Not knowing where to turn for accurate, over-the-horizon radar, which looks at the underlying fundamentals of a company, the vast majority of investors eventually become traders. They become caught up in the process of neurotically shaving points based on the latest buzz, never holding onto anything longer than the officially prognosticated, CNBC pundit consensus-verified sell-by date. This is probably why the smallcap and microcap space scares the hell out of so many people, especially when it comes to biopharma R&D plays whose ramp up phase is notoriously costly, which are really long-haul bets on the tech fundamentals in most cases (and let’s face it, the average talking head knows very little about biotechnology). Whether the sector big boys like it or not, we have crossed the Rubicon with inhalable insulin, and Afreeza is likely here to stay. The patients love it, it seems to help them regulate their glucose levels more easily, it’s easier to deploy, and it appeals to self-conscious consumers (or even those who simply prefer to be discreet). Reasons alone enough to keep Afreeza on the scene, but it is the efficacy of the underlying formulation technology when it comes to addressing post-meal spikes in a smoother fashion that will probably make it a late-game comeback kid.

Take a closer look for yourself, visit www.MannKindCorp.com

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered